Alimera Sciences Now Covered by Analysts at Northland Capital Partners (ALIM)
Analysts at Northland Capital Partners started coverage on shares of Alimera Sciences (NASDAQ:ALIM) in a research report issued to clients and investors on Tuesday, Analyst Ratings.Net reports. The firm set an “outperform” rating and a $5.00 price target on the stock. Northland Capital Partners’ price target points to a potential upside of 34.77% from the company’s current price.
Shares of Alimera Sciences (NASDAQ:ALIM) opened at 3.71 on Tuesday. Alimera Sciences has a 52-week low of $1.26 and a 52-week high of $5.69. The stock’s 50-day moving average is $3.74 and its 200-day moving average is $3.97. The company’s market cap is $117.2 million.
Alimera Sciences (NASDAQ:ALIM) last released its earnings data on Monday, August 12th. The company reported ($0.30) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.24) by $0.06. During the same quarter in the prior year, the company posted ($0.15) earnings per share. Analysts expect that Alimera Sciences will post $-1.18 EPS for the current fiscal year.
Separately, analysts at Northland Securities initiated coverage on shares of Alimera Sciences in a research note to investors on Monday. They set an “outperform” rating on the stock.
Alimera Sciences, Inc is a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.